Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan

Introduction

Triple-negative breast cancer (TNBC) represents a highly aggressive subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and HER2 expression. It accounts for approximately 15-20% of all breast cancers and is associated with poorer prognosis and limited targeted treatment options, primarily relying on chemotherapy. Patients with untreated, advanced, or metastatic TNBC are often in urgent need of more effective therapies to improve survival outcomes.

Recent advances in immunotherapy, particularly PD-1 and PD-L1 inhibitors, have provided new hope; however, many patients are ineligible due to previous treatments or coexisting conditions. For these patients, alternative targeted therapies are critically needed.